Kore Private Wealth LLC reduced its stake in shares of Colgate-Palmolive (NYSE:CL) by 5.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,977 shares of the company’s stock after selling 215 shares during the quarter. Kore Private Wealth LLC’s holdings in Colgate-Palmolive were worth $324,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the stock. Baker Tilly Wealth Management LLC boosted its holdings in shares of Colgate-Palmolive by 1.5% during the second quarter. Baker Tilly Wealth Management LLC now owns 8,406 shares of the company’s stock worth $684,000 after purchasing an additional 127 shares during the period. Horan Securities Inc. lifted its stake in Colgate-Palmolive by 60.1% in the second quarter. Horan Securities Inc. now owns 341 shares of the company’s stock valued at $28,000 after acquiring an additional 128 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in Colgate-Palmolive by 4.6% in the second quarter. Quadrant Capital Group LLC now owns 2,947 shares of the company’s stock valued at $240,000 after acquiring an additional 130 shares during the last quarter. Altfest L J & Co. Inc. lifted its stake in Colgate-Palmolive by 3.7% in the second quarter. Altfest L J & Co. Inc. now owns 3,733 shares of the company’s stock valued at $304,000 after acquiring an additional 133 shares during the last quarter. Finally, EagleClaw Capital Managment LLC lifted its stake in Colgate-Palmolive by 0.4% in the second quarter. EagleClaw Capital Managment LLC now owns 30,494 shares of the company’s stock valued at $2,481,000 after acquiring an additional 133 shares during the last quarter. Institutional investors and hedge funds own 76.28% of the company’s stock.
In other Colgate-Palmolive news, insider Jennifer Daniels sold 20,290 shares of the business’s stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $79.11, for a total value of $1,605,141.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sally Massey sold 610 shares of the business’s stock in a transaction on Tuesday, September 14th. The shares were sold at an average price of $77.18, for a total transaction of $47,079.80. Following the completion of the sale, the insider now directly owns 7,510 shares in the company, valued at approximately $579,621.80. The disclosure for this sale can be found here. Insiders have sold 22,798 shares of company stock worth $1,800,304 in the last ninety days. 0.32% of the stock is currently owned by insiders.
Colgate-Palmolive (NYSE:CL) last announced its earnings results on Thursday, July 29th. The company reported $0.80 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.80. Colgate-Palmolive had a net margin of 15.98% and a return on equity of 293.48%. The business had revenue of $4.26 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the previous year, the firm posted $0.74 earnings per share. Colgate-Palmolive’s revenue was up 9.3% compared to the same quarter last year. Equities research analysts anticipate that Colgate-Palmolive will post 3.23 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, November 15th. Investors of record on Thursday, October 21st will be given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date of this dividend is Wednesday, October 20th. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 58.82%.
CL has been the subject of a number of analyst reports. Evercore ISI reiterated a “buy” rating and issued a $95.00 target price on shares of Colgate-Palmolive in a research note on Sunday, June 20th. UBS Group initiated coverage on shares of Colgate-Palmolive in a research note on Wednesday, June 23rd. They issued a “buy” rating and a $95.00 target price for the company. Bank of America assumed coverage on shares of Colgate-Palmolive in a research note on Tuesday, October 5th. They issued a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $84.00 to $86.00 in a research note on Monday, September 20th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $85.69.
Colgate-Palmolive Co is engaged in the manufacturing and distribution of consumer products. It operates through Oral, Personal and Home Care and Pet Nutrition segments. The Oral, Personal and Home Care segment represents North America, Latin America, Europe, Asia Pacific, and Africa or Eurasia, all of which sell to a variety of retail and wholesale customers and distributors.
Featured Article: Mutual funds are not immune from market timing
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.